CAUTION: The evidence available regarding COVID-19 treatments (even limited to the randomized trial evidence) is very limited and potentially unstable. Much of the available evidence is not published in peer-reviewed final form, and most treatments are currently considered experimental.
MAJOR UPDATE: Topline results from the large-scale RECOVERY trial suggest hydroxychloroquine offers no benefit for 28-day mortality in patients hospitalized with COVID-19. After data had accumulated for 1,542 patients randomized to hydroxychloroquine and 3,132 patients randomized to usual care, the UK Medicines and Healthcare Products Regulatory Agency requested the independent Data Monitoring Committee review the data; as a result of this review, the DMC formally recommended the principal investigators review the unblinded data, which showed 28-day mortality to be 25.7% in the hydroxychloroquine arm died vs. 23.5% in the usual care arm (hazard ratio 1.11; 95% CI 0.98 to 1.26). The trialists also concluded there “was no evidence of beneficial effects on hospital stay duration or other outcomes”, though no data are available for these other outcomes at this time. As a result of these findings, enrollment into the hydroxychloroquine arm of RECOVERY is now closed, but the other arms of the RECOVERY trial remain open to enrollment of additional patients.
The results for clinical trials of treatment that appear below were composed prior to the availability of the above findings from the RECOVERY trial. The findings from the RECOVERY trial will be incorporated into the content below as quickly as possible, but the above results are likely to be practice-changing and provide definitive answers regarding hydroxychloroquine in the treatment of COVID-19.